CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Exenatidedrug
Likely dose
Exenatide 0.05 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00736229
NCT00736229Phase 4Completed
CompareCT.gov

Intensive Exenatide Therapy in Hyperglycemic Patients Admitted to the Coronary Intensive Care Unit

Saint Luke's Health System·interventional·Posted Aug 15, 2008·Updated Nov 20, 2014

In Brief

A Phase 4 clinical trial evaluating Exenatide for Hyperglycemia and 2 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the efficacy of intravenous Exenatide therapy in hyperglycemic patients admitted to the coronary intensive care unit.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperglycemia, Acute Coronary Syndromes, Myocardial Infarction
CountriesUnited States
CollaboratorsAmylin Pharmaceuticals, LLC.

Timeline

Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2008
Enrollment StartAug 1, 2008
Primary CompletionJun 1, 2011
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.9 years ago

Interventions

Exenatidedrug

0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours